

Ref: FOI/GS/ID 8888

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

28 February 2024

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Lung Cancer.

You asked: All questions are shown as received by the Trust.

Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)*
- b. Amivantamab*
- c. Atezolizumab Monotherapy*
- d. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel*
- e. Dabrafenib + Trametinib*
- f. Docetaxel monotherapy or in combination with Carboplatin/Cisplatin*
- g. Durvalumab*
- h. Gemcitabine*
- i. Nitedanib + Docetaxel*
- j. Nivolumab*
- k. Osimertinib*
- l. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)*
- m. Paclitaxel*
- n. Pembrolizumab Monotherapy*
- o. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)*
- p. Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)*
- q. Pemetrexed + Platinum (Carboplatin/Cisplatin)*
- r. RET Inhibitors (Pralsetinib, Selpercatinib)*
- s. Sotorasib*
- t. Tepotinib*
- u. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin*
- v. Other active systemic anti-cancer therapy*
- w. Palliative care only*

Q2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:

- a. Atezolizumab monotherapy
- b. Durvalumab
- c. Gemcitabine
- d. Nivolumab
- e. Osimertinib
- f. Pembrolizumab (Keytruda) Mono
- g. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
- h. Paclitaxel
- i. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
- j. Other active systemic anti-cancer therapy (SACT)
- k. Palliative care only

Trust response:

Data from 1/11/2023-31/1/2024.

Q1	
a.	5
b.	0
c.	1
d.	2
e.	3
f.	1
g.	2
h.	0
i.	1
j.	0
k.	27
l.	3
m.	0
n.	12
o.	4
p.	13
q.	6
r.	1
s.	2
t.	1
u.	11
v.	11
w.	2
Q2	
a.	0
b.	1
c.	0
d.	0
e.	4

f.	0
g.	5
h.	0
i.	4
j.	2
k.	0